{
    "clinical_study": {
        "@rank": "75554", 
        "arm_group": [
            {
                "arm_group_label": "entecavir", 
                "arm_group_type": "Experimental", 
                "description": "entecavir 0.5 mg/day PO"
            }, 
            {
                "arm_group_label": "lamivudine", 
                "arm_group_type": "Active Comparator", 
                "description": "lamivudine 100 mg/day PO"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to prove the superiority of entecavir over lamivudine for\n      preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma\n      on CHOP/R-CHOP."
        }, 
        "brief_title": "Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-Hodgkin Lymphoma", 
            "Hepatitis B Reactivation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "In china, previous studies showed patients with non-Hodgkin lymphoma (NHL) are likely to\n      have hepatitis B virus (HBV) infection. The risk of HBV reactivation is high when patients\n      were treated with CHOP, especially in combination with rituximab. The aim of this study is\n      to compare entecavir with lamivudine, 2 commonly used anti-virus agents, for preventing the\n      risk of HBV reactivation in patients with NHL on CHOP/R-CHOP."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously untreated NHL suitable for CHOP/R-CHOP treatment\n\n          -  Age range 18-80 years old\n\n          -  HBsAg positive with high level of HBV DNA\n\n          -  Eastern Cooperative Oncology Group performance status 0-2\n\n          -  Life expectancy of more than 3 months\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Primary or secondary central nervous system involvement\n\n          -  With hepatitis C virus infection\n\n          -  Previous serious cardiac disease\n\n          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma\n             in-situ of uterine cervix\n\n          -  Pregnant or lactating women\n\n          -  Serious uncontrolled diseases and intercurrent infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01914744", 
            "org_study_id": "LMTG 13-03"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "entecavir", 
                    "lamivudine"
                ], 
                "description": "entecavir 0.5 mg/day PO", 
                "intervention_name": "Entecavir", 
                "intervention_type": "Drug", 
                "other_name": "baraclude"
            }, 
            {
                "arm_group_label": [
                    "entecavir", 
                    "lamivudine"
                ], 
                "description": "lamivudine 100 mg/day PO", 
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug", 
                "other_name": "epivir"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lamivudine", 
                "Entecavir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NHL", 
            "HBV", 
            "entecavir", 
            "lamivudine"
        ], 
        "lastchanged_date": "July 31, 2013", 
        "location": {
            "contact": {
                "email": "pattrick_guo@msn.com", 
                "last_name": "Ye Guo, MD", 
                "phone": "+86 21 64175590", 
                "phone_ext": "8906"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "Ye Guo, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Virus Reactivation in Patients With Non-Hodgkin Lymphoma on CHOP/R-CHOP: a Randomized Phase II Study", 
        "other_outcome": {
            "measure": "Incidence of drug resistance of viral variants", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "overall_contact": {
            "email": "pattrick_guo@msn.com", 
            "last_name": "Ye Guo, MD", 
            "phone": "+86 21 64175590", 
            "phone_ext": "8906"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Ye Guo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Defined by increased level of HBV DNA", 
            "measure": "Incidence rate of HBV reactivation", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01914744"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Ye Guo", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Defined by increased level of alanine transaminase", 
                "measure": "Incidence rate of hepatitis and HBV reactivation-related hepatitis", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Measured by information of treatment delay", 
                "measure": "Incidence rate and median time of treatment delay due to hepatitis", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Measured by information of HBV DNA level normalization", 
                "measure": "Incidence rate and median time of HBV DNA level normalization", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}